Synonym
Cyclic HPMPC dihydrate; Cyclic cidofovir dihydrate; GS 0930 dihydrate; GS0930 dihydrate; GS-0930 dihydrate
IUPAC/Chemical Name
4-Amino-1-((2-hydroxy-1,4,2-dioxaphosphorinan-5-yl)methyl)-2(1H)-pyrimidinone, p-oxide (S) dihydrate
InChi Key
RVBOXKBZYVVZJW-ILKKLZGPSA-N
InChi Code
InChI=1S/C8H12N3O5P.2H2O/c9-7-1-2-11(8(12)10-7)3-6-4-16-17(13,14)5-15-6;;/h1-2,6H,3-5H2,(H,13,14)(H2,9,10,12);2*1H2/t6-;;/m0../s1
SMILES Code
O.O.NC1=NC(=O)N(C[C@H]2COP(=O)(O)CO2)C=C1
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
|
Solvent |
mg/mL |
mM |
Solubility |
Soluble in DMSO |
0.0 |
100.00 |
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
297.20
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Cundy KC, Bidgood AM, Lynch G, Shaw JP, Griffin L, Lee WA. Pharmacokinetics, bioavailability, metabolism, and tissue distribution of cidofovir (HPMPC) and cyclic HPMPC in rats. Drug Metab Dispos. 1996 Jul;24(7):745-52. PMID: 8818571.
2: Smee DF, Bailey KW, Sidwell RW. Comparative effects of cidofovir and cyclic HPMPC on lethal cowpox and vaccinia virus respiratory infections in mice. Chemotherapy. 2003 Jun;49(3):126-31. doi: 10.1159/000070618. PMID: 12815205.
3: Oliyai R, Shaw JP, Sueoka-Lennen CM, Cundy KC, Arimilli MN, Jones RJ, Lee WA. Aryl ester prodrugs of cyclic HPMPC. I: Physicochemical characterization and in vitro biological stability. Pharm Res. 1999 Nov;16(11):1687-93. doi: 10.1023/a:1018945713623. PMID: 10571273.
4: Oliyai R, Arimilli MN, Jones RJ, Lee WA. Pharmacokinetics of salicylate ester prodrugs of cyclic HPMPC in dogs. Nucleosides Nucleotides Nucleic Acids. 2001 Apr-Jul;20(4-7):1411-4. doi: 10.1081/NCN-100002566. PMID: 11563033.
5: Cundy KC, Lynch G, Shaw JP, Hitchcock MJ, Lee WA. Distribution and metabolism of intravitreal cidofovir and cyclic HPMPC in rabbits. Curr Eye Res. 1996 May;15(5):569-76. doi: 10.3109/02713689609000768. PMID: 8670758.